Klatt E C, Wasef E S, Wong E T
Am J Clin Pathol. 1982 Mar;77(3):280-4. doi: 10.1093/ajcp/77.3.280.
Analysis of cost-effectiveness of a laboratory test requires not only calculating the cost of doing the test in the laboratory, but also determining the clinical effectiveness of the data produced. In this hospital, creatine kinase (CK) is available only as part of a 19-test panel. The cost per CK result was $0.64, based on cost of material and labor used exclusively for CK. To evaluate the yield from CK as a screening test, 252 patients were investigated with CK greater than 200 U/l on a biochemical panel within 24 hours of admission. The authors found no instance of a new diagnosis established because of the initially elevated CK. To complete the analysis of cost-effectiveness, the authors estimated the daily workload for CK tests needed for diagnostic purposes. Of the 600 CK tests done daily as part of biochemical panels, no more than 40 were clinically necessary. The true cost for a useful CK test was $9.60--15 times higher than the apparent cost of $0.64.
对一项实验室检测进行成本效益分析,不仅需要计算在实验室进行该检测的成本,还需要确定所产生数据的临床有效性。在这家医院,肌酸激酶(CK)仅作为一项包含19项检测的组合检测的一部分提供。基于专门用于CK检测的材料和劳动力成本,每项CK检测结果的成本为0.64美元。为了评估CK作为筛查检测的收益,对252例患者进行了调查,这些患者在入院后24小时内生化检测组合中的CK大于200 U/l。作者未发现因最初CK升高而确立新诊断的情况。为了完成成本效益分析,作者估算了诊断所需的CK检测的每日工作量。作为生化检测组合的一部分,每天进行600次CK检测,其中临床上必要的检测不超过40次。一次有用的CK检测的实际成本为9.60美元,是表面成本0.64美元的15倍。